Similar results in CAD patients have been described by Ota et al. [68], showing significant LDL-C reduction in the PCSK9 group (difference of 59.3 mg/dL, p < 0.001), with absolute and normal PAV reduction and LCBI regression being significantly more pronounced in the PCSK9 arm. The gene discussed is PCSK9; the disease is coronary artery disorder.